Can Cannabis Cause Acute Hallucinations Without Explaining Every Such Event? A Controlled-Dosing Case

A carefully documented human case shows that acute hallucinations can occur after THC administration, but it does not establish how often they occur or explain an unrelated person’s symptoms. The distinction between observing an unusual response and estimating population risk is central to this report.

What happened during the study?

Barrett and colleagues described a healthy 30-year-old man who experienced hallucinations and substantial functional incapacity after vaporizing cannabis containing 25 mg THC during controlled research. The most prominent episode lasted approximately 90 minutes.

The participant did not show the same response after the same nominal THC dose was smoked or after a lower vaporized dose. The case therefore should not be reduced to a claim that any particular labeled dose invariably produces hallucinations, regardless of route.

Blood concentration did not provide a simple explanation

The participant’s blood THC concentrations were not unusually elevated relative to those of other participants in the study. That observation limits an explanation based solely on an exceptional measured blood value. Individual response and exposure conditions remain relevant.

The researchers compared standardized subjective-effect ratings with archival data from other hallucinogenic drugs. The cannabis response had a distinctive profile. This was not a randomized head-to-head trial establishing that THC is universally stronger or weaker than those drugs.

What the report does and does not establish

The event occurred in a controlled administration setting, providing stronger exposure documentation than a retrospective account with unknown products. Nevertheless, it remains a single case. It cannot yield an incidence estimate, identify all susceptibility factors, or establish a universal concentration threshold.

The authors did not report lasting hallucinogen-persisting perception disorder in this participant. An intense acute episode should therefore not be described as demonstrated permanent injury on the basis of this paper.

Interpreting symptoms in an individual case

Evidence review should identify the product, route, timing, other exposures, medical context, observed behavior, and available measurements. This paper establishes a plausible documented response, not a diagnostic shortcut. Attributing hallucinations in another person requires independent evaluation of competing explanations and the chronology of that person’s event.

For related context, see our discussion of how edible and vaporized cannabis differ in timing.

Primary research

Frederick S. Barrett; Nicolas J. Schlienz; Natalie Lembeck; Muhammad Waqas; Ryan Vandrey. “Hallucinations” Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs. Cannabis and Cannabinoid Research (2018). DOI: 10.1089/can.2017.0052.